Moexipril drug interactions: Difference between revisions

Jump to navigation Jump to search
m (Changed protection level for "Moexipril drug interactions" ([Edit=Allow only autoconfirmed users] (expires 17:47, 28 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 17:47, 28 February 2014 (UTC))))
 
No edit summary
Line 1: Line 1:
{{CMG}}
__NOTOC__
__NOTOC__
{{Moexipril}}
{{CMG}}; {{AE}} {{AM}}
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, COATED [PADDOCK LABORATORIES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c657e39-edeb-4fa1-9a67-78eed3702494 | publisher =  | date =  | accessdate = }}</ref>
==References==
{{Reflist}}
{{FDA}}
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]


==Major Interactions==
==Major Interactions==

Revision as of 17:54, 14 February 2014


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]

Moexipril

Moexipril and Hydrochlorothiazide tablet

Overview

Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.

Category

Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]


[1]


References

  1. "MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, COATED [PADDOCK LABORATORIES, INC.]".

Adapted from the FDA Package Insert.

Major Interactions

Moderate Interactions

Minor Interactions


Adapted from the FDA Package Insert.